ArticleJournal of pharmacokinetics and pharmacodynamics2026
On the existence conditions of interaction indices in response surface models.
Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Response-surface models (RSMs) are widely used to characterize the combined effects of two agents and to classify their interaction as additivity, synergy, or antagonism. In this context, an interaction index is frequently used as a quantitative measure. However, estimation of the interaction index outside feasible ranges may result in complex-valued or biologically implausible predictions in certain regions of the input domain, thereby limiting the validity of the model. This paper introduces a feasibility analysis framework that distinguishes between isobole-level feasibility (i.e. the existence of well-defined isoboles at a given effect level) and global feasibility (i.e. well-posedness across the entire domain). The analysis explicitly characterizes the singular sets that arise when feasibility conditions are violated, thereby explaining when and how models fail. The approach is demonstrated on three canonical models, i.e. Greco, Minto, and Finney, and supported by numerical illustrations, offering practical guidance for systematic and robust parameter selection in drug combination studies, toxicology, and process engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.